Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
March 29, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 22, 2004
- REGULATORY NEWS IN BRIEF
March 22, 2004
- Impact of NHI Price Revisions Ranges from 3% to 7%
March 22, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
March 22, 2004
- New NHI Prices Gazetted on March 5
March 22, 2004
- BUSINESS NEWS IN BRIEF
March 22, 2004
- Japan CRO Association Holds 10th Anniversary Symposium
March 22, 2004
- Novartis Has 58 Products in PII, PIII in US: CEO Ebeling
March 22, 2004
- Meet the Leaders (31)
March 22, 2004
- Banyu to "Seriously Go After the Japanese Market": Mr Hirate
March 22, 2004
- Annual Business Results
March 22, 2004
- Aiming to Be a "Global Mega-player" via Merger: Dr Aoki of Fujisawa
March 22, 2004
- WORLD NEWS IN BREIF
March 22, 2004
- Eisai Seeks Efficiency, Not Scale: Mr Naito
March 22, 2004
- DIAGNOSTIC NEWS IN BRIEF
March 22, 2004
- Pfizer Japan Aims to Boost MR Productivity by 50% in 5 Years: Mr Bootes
March 22, 2004
- OTC NEWS IN BRIEF
March 22, 2004
- BULLETIN
March 22, 2004
- MEDICAL DEVICE NEWS IN BRIEF
March 22, 2004
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…